GAS5 and breast cancer: In addition, GAS5 expression was significantly downregulated in trastuzumab-resistant breast cancer patients, gefitinib-resistant lung adenocarcinoma cell lines and erlotinib-resistant glioma cell line, which was of great clinical significance for targeted therapy [28-30].